Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats

Coronavirus disease 2019 (COVID-19), caused by a new strain of coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly worldwide. Nafamostat mesylate (NFM) suppresses transmembrane serine protease 2 and SARS-CoV-2 S protein-mediated fusion. In this study...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Ji-Hyun Kang, Young-Jin Kim, Min-Seok Yang, Dae Hwan Shin, Dong-Wook Kim, Il Yeong Park, Chun-Woong Park
Format:	Article
Language:	English
Published:	MDPI AG 2021-09-01
Subjects:	COVID-19 nafamostat mesylate dry powder inhaler lecithin mannitol co-spray
Online Access:	https://www.mdpi.com/1999-4923/13/9/1519